Andesa Financial Management Inc. Has $279,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Andesa Financial Management Inc. increased its holdings in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 10.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,383 shares of the medical research company’s stock after acquiring an additional 229 shares during the period. Andesa Financial Management Inc.’s holdings in Edwards Lifesciences were worth $279,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. EverSource Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $29,000. American National Bank boosted its position in Edwards Lifesciences by 99.1% during the first quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 116 shares during the last quarter. Rinkey Investments purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $29,000. JJJ Advisors Inc. increased its position in Edwards Lifesciences by 79.1% in the 1st quarter. JJJ Advisors Inc. now owns 283 shares of the medical research company’s stock worth $33,000 after purchasing an additional 125 shares during the last quarter. Finally, Gemmer Asset Management LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $36,000. 82.54% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 1.2 %

EW stock opened at $106.12 on Friday. Edwards Lifesciences Co. has a 1-year low of $85.58 and a 1-year high of $131.73. The company has a current ratio of 3.37, a quick ratio of 2.60 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $97.35 and its 200-day moving average is $105.35. The firm has a market cap of $65.79 billion, a P/E ratio of 45.94, a P/E/G ratio of 3.09 and a beta of 1.12.

Edwards Lifesciences (NYSE:EWGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The business’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the company earned $0.64 earnings per share. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Michael A. Mussallem sold 32,550 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $94.82, for a total value of $3,086,391.00. Following the transaction, the chief executive officer now directly owns 157,353 shares of the company’s stock, valued at approximately $14,920,211.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 19,875 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $86.96, for a total value of $1,728,330.00. Following the completion of the sale, the chief executive officer now owns 157,353 shares in the company, valued at approximately $13,683,416.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 32,550 shares of the stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $94.82, for a total value of $3,086,391.00. Following the completion of the transaction, the chief executive officer now owns 157,353 shares in the company, valued at $14,920,211.46. The disclosure for this sale can be found here. Insiders sold 120,854 shares of company stock worth $11,439,096 in the last quarter. 1.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

EW has been the subject of a number of analyst reports. Canaccord Genuity Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $115.00 to $106.00 in a research note on Friday, July 29th. Canaccord Genuity Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $115.00 to $106.00 in a research report on Friday, July 29th. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday. Cowen lowered their price objective on Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. Finally, Truist Financial reduced their target price on Edwards Lifesciences from $140.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, July 20th. Three research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $126.19.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.